TNSMS24

Update on Advanced Anti-CD20 Therapeutics to Improve Outcomes for Patients with Multiple Sclerosis

Friday, July 19th, 2024 from 6:30pm – 7:30pm CDT
Name*

First NameLast Name
Credentials
State Licensed to Practice in
Email*
example@example.com
1. All of the following prescreening labs are needed prior to start an anti-CD20 monoclonal antibody EXCEPT:*

a. Hepatitis B surface antigen and hepatitis B core antibodyb. Complete blood countc. Cholesterol panel and hemoglobin A1cd. Transaminases/liver function tests
2. In the Ultimate I/II studies of ublituximab, which of the following is FALSE?*

a. Results demonstrated a decrease in thalamic volume lossb. A decrease in MS activity was not reflected by multiple biomarkersc. Results demonstrated a decrease in MS Pathway Scoresd. Results demonstrated a decrease in MS Activity Scores
3. Your next clinic patient is a 35-year-old man who presents with a new diagnosis of multiple sclerosis. He is concerned about his increased risk for disability in the future and has researched different treatments options online but is unsure of which one to choose. With all other conditions and factors being equal, along without consideration of side effects, which of the following are considered to be high efficacy medications?*

a. Interferon betab. Alemtuzumabc. Teriflunomided. Anti-CD20 monoclonal antibodiese. Both B and D
4. What is TRUE about an anti-CD 20 therapeutic’s impact on peripheral B-cells?*

a. There is no effect on peripheral B-cells with anti-CD20 therapeutics.b. B-cells are not affected by anti-CD 20 therapeutics.c. If peripheral B-cells are targeted, the B-cells in the CNS may not need to be targeted.d. Ongoing treatment with an anti-CD 20 therapeutic does not affect B-cell depletion in the periphery.
Overall Activity Feedback

Please rate the extent to which this activity met the following objectives:

	Poor	Fair	Good	Very Good	Excellent
Review recent efficacy and safety data for anti-CD20 therapeutics to treat patients with multiple sclerosis
Recognize the current unmet needs of patients with MS and the role of anti-CD20 therapeutics to improve outcomes for these patients

Please provide us with feedback regarding your experience at the activity:

	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Please rate the faculty on their overall teaching ability:

	Poor	Fair	Good	Very Good	Excellent
Ann D. Bass, MD

Do you feel this activity was fair balanced and free of commercial bias?

YesNo
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Credit
courseTitle
Should be Empty:

Overall Activity Feedback